CS
VRTX icon

Cannell & Spears’s Vertex Pharmaceuticals VRTX Stock Holding History

Cannell & Spears’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$977K Sell
1,966
-17
-0.9% -$7.53K 0.02% 255
2026
Q1 		$885K Buy
1,983
+23
+1% +$10.7K 0.02% 250
2025
Q4 		$889K Hold
1,960
– – 0.02% 249
2025
Q3 		$768K Buy
1,960
+88
+5% +$36.8K 0.01% 255
2025
Q2 		$833K Sell
1,872
-37
-2% -$17.1K 0.02% 242
2025
Q1 		$926K Sell
1,909
-32
-2% -$14.9K 0.02% 229
2024
Q4 		$782K Buy
1,941
+3
+0.2% +$1.39K 0.02% 255
2024
Q3 		$901K Sell
1,938
-209
-10% -$100K 0.02% 249
2024
Q2 		$1.01M Sell
2,147
-380
-15% -$165K 0.02% 221
2024
Q1 		$1.06M Buy
+2,527
New +$1.07M 0.02% 222

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Cannell & Spears's VRTX Position: Q2 2026 in Review

Cannell & Spears reduced its Vertex Pharmaceuticals (VRTX) stake by 0.86% in Q2 2026, selling an estimated $7.53K and leaving 1,966 shares worth $977K. The position accounts for 0.02% of the portfolio, ranked #255.

Cannell & Spears first reported a position in VRTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.06M in Q1 2024. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Cannell & Spears held 1,966 shares of Vertex Pharmaceuticals worth $977K as of Q2 2026.
  • Cannell & Spears sold 17 Vertex Pharmaceuticals shares in Q2 2026, an estimated $7.53K.
  • Vertex Pharmaceuticals made up 0.02% of Cannell & Spears's portfolio in Q2 2026, its #255 holding.
  • Cannell & Spears first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Cannell & Spears's Vertex Pharmaceuticals position peaked at $1.06M in Q1 2024.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Cannell & Spears's 13F filing for Q2 2026, filed 11 Aug 2026.